P2X7R antagonist protects against renal injury in mice with adriamycin nephropathy

Yanji Zhu1, Min Liu1, Wenlong Xun1

  • 1Department of Pediatrics, People's Hospital of Rizhao Affiliated to Jining Medical University, Rizhao, Shandong 276800, P.R. China.

Insights

Inhibiting the purinergic P2X7 receptor (P2X7R) pathway alleviates adriamycin (ADR) induced kidney injury by reducing inflammation and apoptosis. This study highlights P2X7R as a potential therapeutic target for ADR nephropathy.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Adriamycin (ADR) nephropathy is a significant cause of kidney injury.
  • Activation of the purinergic P2X7 receptor (P2X7R) is implicated in experimental nephritis.

Purpose of the Study:

  • To investigate the mechanism of P2X7R in ADR-induced nephropathy in mice.
  • To evaluate the protective effect of a P2X7R antagonist against ADR nephropathy.

Main Methods:

  • ADR was administered to induce nephropathy in mice.
  • Mice were treated with the P2X7R antagonist A438079.
  • Kidney injury markers, inflammatory cytokines (IL-1β, IL-18), P2X7R expression, ox-LDL, CXCL16, apoptosis markers (Bax, caspase-3), and NLRP3 were assessed.
  • TUNEL assay was used to detect apoptosis.

Main Results:

  • ADR-induced nephropathy was characterized by decreased weight, increased proteinuria, decreased serum albumin, and increased total cholesterol.
  • ADR significantly increased the expression of IL-1β, IL-18, P2X7R, ox-LDL, CXCL16, Bax, caspase-3, NLRP3, and apoptosis in renal tissues.
  • Treatment with A438079 attenuated these ADR-induced changes.

Conclusions:

  • P2X7R, ox-LDL, and CXCL16 are associated with ADR nephropathy.
  • Inhibition of P2X7R may reduce ox-LDL expression via the CXCL16 pathway, alleviating kidney injury.
  • Activated P2X7R promotes inflammation and apoptosis through the P2X7R/NLRP3 pathway, contributing to ADR nephropathy.